Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.43 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL346461 | 1.00 | NAAA (0.49) | NAAACASP3CASP7RAB9ATPSAB1 | |
| SCHEMBL15807584 | 0.91 | SMN1; SMN2 (0.47) | NAAACASP3CASP7RAB9AFAAH | |
| SCHEMBL17186412 | 0.89 | FAAH (0.48) | NAAACASP3CASP7LTB4RLTB4R2 | |
| SCHEMBL7423431 | 0.89 | FAAH (0.48) | NAAACASP3CASP7LTB4RLTB4R2 | |
| SCHEMBL28888979 | 0.87 | MAPK1 (0.48) | NAAARAB9APLA2G4AALDH1A1 | |
| SCHEMBL28888976 | 0.87 | MAPK1 (0.48) | NAAARAB9APLA2G4AALDH1A1 | |
| SCHEMBL345276 | 0.85 | NAAA (0.57) | NAAAFAAHPPARA | |
| SCHEMBL6334745 | 0.85 | NAAA (0.57) | NAAAFAAHPPARA | |
| SCHEMBL345275 | 0.85 | NAAA (0.57) | NAAAFAAHPPARA | |
| SCHEMBL23327036 | 0.85 | CASP3 (0.48) | NAAACASP3CASP7RAB9ATPSAB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015942-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | NAAA 363/4885CASP3 696/4885CASP7 767/4885 |
| US-20140243334-A1 | SUBSTITUTED HYDOXAMIC ACIDS AND USES THEREOF | HDAC6, H1-3, H1-5 | NAAA 230/4885CASP3 734/4885CASP7 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.